Monthly Archives: September 2021

Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study

CONCLUSIONS: CBMs improve the perception of pain, pruritus, wound healing, and well-being in EB patients and reduced concomitant medication use. Nevertheless, a direct relation between the use of CBMs and reduction of the above-mentioned symptoms cannot be proven by these data. Therefore, future controlled studies using pharmaceutically standardised CBM preparations in EB are warranted to delineate the risks and benefits of CBMs. Continue reading






Comments Off on Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study